Redin Claire, Gérard Bénédicte, Lauer Julia, Herenger Yvan, Muller Jean, Quartier Angélique, Masurel-Paulet Alice, Willems Marjolaine, Lesca Gaétan, El-Chehadeh Salima, Le Gras Stéphanie, Vicaire Serge, Philipps Muriel, Dumas Michaël, Geoffroy Véronique, Feger Claire, Haumesser Nicolas, Alembik Yves, Barth Magalie, Bonneau Dominique, Colin Estelle, Dollfus Hélène, Doray Bérénice, Delrue Marie-Ange, Drouin-Garraud Valérie, Flori Elisabeth, Fradin Mélanie, Francannet Christine, Goldenberg Alice, Lumbroso Serge, Mathieu-Dramard Michèle, Martin-Coignard Dominique, Lacombe Didier, Morin Gilles, Polge Anne, Sukno Sylvie, Thauvin-Robinet Christel, Thevenon Julien, Doco-Fenzy Martine, Genevieve David, Sarda Pierre, Edery Patrick, Isidor Bertrand, Jost Bernard, Olivier-Faivre Laurence, Mandel Jean-Louis, Piton Amélie
Département de Médicine translationnelle et Neurogénétique, IGBMC, CNRS UMR 7104/INSERM U964/Université de Strasbourg, Illkirch, France Chaire de Génétique Humaine, Collège de France, Illkirch, France.
Laboratoire de diagnostic génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
J Med Genet. 2014 Nov;51(11):724-36. doi: 10.1136/jmedgenet-2014-102554. Epub 2014 Aug 28.
Intellectual disability (ID) is characterised by an extreme genetic heterogeneity. Several hundred genes have been associated to monogenic forms of ID, considerably complicating molecular diagnostics. Trio-exome sequencing was recently proposed as a diagnostic approach, yet remains costly for a general implementation.
We report the alternative strategy of targeted high-throughput sequencing of 217 genes in which mutations had been reported in patients with ID or autism as the major clinical concern. We analysed 106 patients with ID of unknown aetiology following array-CGH analysis and other genetic investigations. Ninety per cent of these patients were males, and 75% sporadic cases.
We identified 26 causative mutations: 16 in X-linked genes (ATRX, CUL4B, DMD, FMR1, HCFC1, IL1RAPL1, IQSEC2, KDM5C, MAOA, MECP2, SLC9A6, SLC16A2, PHF8) and 10 de novo in autosomal-dominant genes (DYRK1A, GRIN1, MED13L, TCF4, RAI1, SHANK3, SLC2A1, SYNGAP1). We also detected four possibly causative mutations (eg, in NLGN3) requiring further investigations. We present detailed reasoning for assigning causality for each mutation, and associated patients' clinical information. Some genes were hit more than once in our cohort, suggesting they correspond to more frequent ID-associated conditions (KDM5C, MECP2, DYRK1A, TCF4). We highlight some unexpected genotype to phenotype correlations, with causative mutations being identified in genes associated to defined syndromes in patients deviating from the classic phenotype (DMD, TCF4, MECP2). We also bring additional supportive (HCFC1, MED13L) or unsupportive (SHROOM4, SRPX2) evidences for the implication of previous candidate genes or mutations in cognitive disorders.
With a diagnostic yield of 25% targeted sequencing appears relevant as a first intention test for the diagnosis of ID, but importantly will also contribute to a better understanding regarding the specific contribution of the many genes implicated in ID and autism.
智力残疾(ID)具有高度的遗传异质性。数百个基因已被证实与单基因形式的ID相关,这使得分子诊断变得极为复杂。三联外显子测序最近被提议作为一种诊断方法,但全面应用成本过高。
我们报告了一种替代策略,即对217个基因进行靶向高通量测序,这些基因在以ID或自闭症为主要临床问题的患者中曾有过突变报道。我们对106例病因不明的ID患者进行了分析,这些患者此前已接受过阵列比较基因组杂交(array-CGH)分析和其他基因检测。这些患者中90%为男性,75%为散发病例。
我们鉴定出26个致病突变:16个位于X连锁基因(ATRX、CUL4B、DMD、FMR1、HCFC1、IL1RAPL1、IQSEC2、KDM5C、MAOA、MECP2、SLC9A6、SLC16A2、PHF8)中,10个为常染色体显性基因的新生突变(DYRK1A、GRIN1、MED13L、TCF4、RAI1、SHANK3、SLC2A1、SYNGAP1)。我们还检测到4个可能的致病突变(如在NLGN3中),需要进一步研究。我们为每个突变的因果关系判定提供了详细的推理过程以及相关患者的临床信息。在我们的队列中,有些基因被多次检测到突变,这表明它们与更常见的ID相关病症有关(KDM5C、MECP2、DYRK1A、TCF4)。我们强调了一些意外的基因型与表型的相关性,在偏离经典表型的患者中,与特定综合征相关的基因中发现了致病突变(DMD、TCF4、MECP2)。我们还为先前候选基因或突变在认知障碍中的作用提供了额外的支持性(HCFC1、MED13L)或非支持性(SHROOM4、SRPX2)证据。
靶向测序的诊断率为25%,作为ID诊断的首选检测方法似乎是合理的,而且重要的是,这也将有助于更好地理解众多与ID和自闭症相关基因的具体作用。